(NASDAQ: GRFS) Grifols Sa's forecast annual revenue growth rate of 7.84% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.87%.
Grifols Sa's revenue in 2024 is $7,088,147,311.On average, 1 Wall Street analysts forecast GRFS's revenue for 2024 to be $5,255,504,703,574, with the lowest GRFS revenue forecast at $5,255,504,703,574, and the highest GRFS revenue forecast at $5,255,504,703,574.
In 2025, GRFS is forecast to generate $5,461,049,243,321 in revenue, with the lowest revenue forecast at $5,461,049,243,321 and the highest revenue forecast at $5,461,049,243,321.